LSDI vs. PBLA, BDRX, GRI, NBSE, INM, SBFM, ATNF, PRFX, ALLR, and QLGN
Should you be buying Lucy Scientific Discovery stock or one of its competitors? The main competitors of Lucy Scientific Discovery include Panbela Therapeutics (PBLA), Biodexa Pharmaceuticals (BDRX), GRI Bio (GRI), NeuBase Therapeutics (NBSE), InMed Pharmaceuticals (INM), Sunshine Biopharma (SBFM), 180 Life Sciences (ATNF), PainReform (PRFX), Allarity Therapeutics (ALLR), and Qualigen Therapeutics (QLGN). These companies are all part of the "pharmaceutical preparations" industry.
Panbela Therapeutics (NASDAQ:PBLA) and Lucy Scientific Discovery (NASDAQ:LSDI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.
Panbela Therapeutics presently has a consensus target price of $500.00, indicating a potential upside of 131,548.24%. Given Lucy Scientific Discovery's higher possible upside, equities analysts plainly believe Panbela Therapeutics is more favorable than Lucy Scientific Discovery.
Panbela Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Lucy Scientific Discovery has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Lucy Scientific Discovery has higher revenue and earnings than Panbela Therapeutics. Lucy Scientific Discovery is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Panbela Therapeutics and Panbela Therapeutics both had 2 articles in the media. Panbela Therapeutics' average media sentiment score of 0.44 beat Lucy Scientific Discovery's score of 0.00 indicating that Lucy Scientific Discovery is being referred to more favorably in the news media.
Panbela Therapeutics received 17 more outperform votes than Lucy Scientific Discovery when rated by MarketBeat users. However, 100.00% of users gave Lucy Scientific Discovery an outperform vote while only 69.23% of users gave Panbela Therapeutics an outperform vote.
Panbela Therapeutics' return on equity of -294.74% beat Lucy Scientific Discovery's return on equity.
4.4% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 72.6% of Lucy Scientific Discovery shares are owned by institutional investors. 0.0% of Panbela Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Lucy Scientific Discovery beats Panbela Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Lucy Scientific Discovery News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSDI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LSDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucy Scientific Discovery Competitors List
Related Companies and Tools
